Outcome of Board Meeting

.. .. .. Narayana Health Date of submission: October 30, 2026 To, To, The Secretary The Secretary Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Mumbai – 400 051 Dalal Street, Mumbai – 400 001 Scrip Code – 539551 (EQ), 975516 & 976418 Scrip Code- NH Dear Sir/Madam, Sub: Outcome of the Board Meeting held on October 30, 2026 Pursuant to Regulation 30 read with Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company at its meeting held today, i.e. October 30, 2026 (Friday) inter alia, has approved the unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026 together with the Limited Review Report reviewed by the Audit Committee and approved by the Board of Directors. A copy of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 together with Limited Review Report is enclosed as Annexure- I for your information. The meeting of the Board of Directors commenced at 03:30 P.M. IST and ended at 05:50 P.M. IST. This is for your information and records. Thanking you, Yours faithfully For Narayana Hrudayalaya Limited Sridhar S. Group Company Secretary, Legal & Compliance Officer Encl.: as above Narayana Hrudayalaya Limited GIN: L85110KA2000PLC027497 Registered Office Address: 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru -560099 Corporate Office Address: 9th & 8th Floor, Plot No. 84, P hase 1, West Avenue-1, Electronics City, Bengaluru -560100 Tel +91 80500 09318 Website: www.narayanahealth.org ~Email: ~ info@narayanahealth.org Annexure-1 Deloitte Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Haskins & Sells LLP Bengaluru – 560 001 Karnataka, India Tel: +91 80 6188 6000 Fax: +91 80 6188 6011 INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF NARAYANA HRUDAYALAYA LIMITED 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of NARAYANA HRUDAYALAYA LIMITED (“the Company”), for the quarter and six months ended September 30, 2026 (“the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”). 2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm’s Registration No. 117366W/W-100018) SATHYA Digitally signed by SATHYA PRAMOD PRAMOD KOUSHIK Date: 2026.10.30 17:08:21 KOUSHIK +05'30' Sathya P. Koushik Partner (Membership No. 206920) UDIN: 26206920SHSAOK2063 Place: Bengaluru Date: October 30, 2026 SPK/SG/TG/AB/2026 Regd Office :31st Floor, Tower 3, One International Center, Senapati Bapat Marg, Elphinstone Road (West), Mumbai – 400013 Narayana Hrudayalaya limited Registered office: No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India Corporate office : 8th & 9th ~loor, No. 84, Phase 1, West Avenue -1, Electronics Qty, Sengaluru, 560100, Karnataka, India CIN: l85110KA2000PLC027497, Website: www.narayanahealth.org, Email: investorrelations@narayanahealth.org STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS mR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026 (~ in million e.cept per share data) Quarter ended Six months ended Year Ended SI. No. Particulars 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1. Income (a) Revenue from operations 11,853.77 10,971.02 10,191.69 22,824.79 19,623.10 39,751.41 (b) Other iricome (refer note 4) 433.50 304.13 170.88 737.63 335.24 1,764.34 Total income 12,287.27 11,275.15 10,362.57 23,562.42 19,958.34 41,515.75 2. Expenses (a) Purchases of medical consumables, drugs, surgical instruments and 2,773.33 2,599.81 2,355.76 5,373.14 4,567.07 9,134.03 other consumables (b} Changes in inventories of medical consumables, drugs, surgical (20.32) (29.77) 11.00 (50.09) 39.29 30.53 instruments and other consumables -(Increase)/ Decrease (c) Employee benefits expense 1,964.18 1,912.19 1,804.35 3,876.37 3,565.90 7,053.80 (d) Professional fees to doctors 2,335.50 2,201.89 2,012.09 4,537.39 3,947.71 8,189.31 (e) Other expenses 2,188.97 1,895.68 1,717.98 4,084.65 3,422.44 6,949.26 Expenses before depreciation and amortisation, finance costs and exceptional items 9,24L66 8,579.80 7,901.18 17,821.46 15,542.41 31,356.93 3. Earnings before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITOA) 3,045.61 2,695.35 2,461.39 5,740.96 4,415.93 10,158.82 4. Finance costs 352.30 336.66 285.78 688.96 592.01 1,271.16 5. Depreciation and amortisation expense 501.09 481.48 462.66 982.57 938.24 1,914.78 6. Total expenses (2<4+5) 10,095.05 9,397.94 8,649.62 19,492.99 17,072.66 34,542.87 7. Profit before tax and exceptional items (1-6) 2,192.22 1,877.21 1,712.95 4,069.43 2,885.68 6,972.88 8. Exceptional item (refer note 8) - (452.76) 9. Profit before tax (7+8) 2,192.22 1,877.21 1,712.95 4,069.43 2,885.68 6,520.12 10. Tax expense (a) Current tax •Current year 418.93 481.11 315.79 900.04 602.40 1,564.92 (b) Deferred tax charge/(credit) 17.03 17.55 18.36 34.58 30.77 (75.93) Total tax expense 435.96 498.66 334.15 934.62 633.17 1,488.99 11. Net Profit for the period/ year (9-10) 1,756.26 1,378.55 1,378.80 3,134.81 2,252.51 5,031.13 12. Other comprehensive income Items that will not be reclassified subsequently to profit or loss (i) Re-measurement gains/(losses) on defined benefit plans 13.38 (46.38) 4.13 (33.00) (3.51) 9.45 (ii) Income tax [Showing first 8,000 characters — download PDF for full document]